SLC5A2 and hydrops fetalis: Moreover, the cardioprotective effect of SGLT2 inhibitors extends to a reduction in CV mortality and in HF hospitalizations in HF across the LVEF spectrum, independent of its glucose-lowering effect, making the drug a mainstay in the management of HFrEF, HFmrEF, and HFpEF.